Hycamtin
(Topotecan)ApprovedSmall molecule
Topotecan is used to treat certain types of cancer, including ovarian cancer, small cell lung cancer, and cervical cancer. It works by stopping cancer cells from dividing and growing.[2] Hycamtin is currently approved and in use across 36 indications[4].[1]
Hycamtin is one of 567 small molecule programs targeting Ovarian Cancer. It is currently in Approved.
36
Indications
222
Total Trials
41
Active Trials
566
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 36 indications
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Vepesid
AAvyxa
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Hycamtin
MMeitheal
Approved
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Nexavar
BayerPhase 3
Cellcept
RochePhase 3
Trexall
Jazz PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer36 trials
Show 33 more trials
Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
Unknown status·—·Phase 2·NCT04213937·386 enrolled
Ovarian Cancer26 trials
Show 23 more trials
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Terminated·—·Phase 1/2·NCT00526799·30 enrolled
Neuroblastoma10 trials
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
Active, not recruiting·NNew Approaches to Neuroblastoma Therapy Consortium·Phase 1·NCT02298348·18 enrolled
Show 7 more trials
High-Risk Neuroblastoma Chemotherapy Without G-CSF
Completed·—·N/A·NCT02786719·13 enrolled
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05303727·64 enrolled
Cervical Cancer8 trials
Show 5 more trials
Lung Cancer6 trials
Show 3 more trials
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
Unknown status·—·Phase 2·NCT02980809·60 enrolled
72 more indications
Fallopian Tube Cancer5 trials
Glioma4 trials
Retinoblastoma4 trials
A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma
Terminated·—·Phase 2·NCT04455139·2 enrolled
Primary Peritoneal Cancer3 trials
Chemotherapy3 trials
Advanced Solid Tumors3 trials
Endometrial Cancer3 trials
Non-Small Cell Lung Cancer3 trials
Multiple Myeloma3 trials
Solid Tumors3 trials
Cervical Carcinoma3 trials
Refractory Solid Tumors3 trials
Medulloblastoma2 trials
Patients With Advanced Solid Tumors2 trials
Lymphoma2 trials
Primary Peritoneal Carcinoma2 trials
Acute Myeloid Leukemia2 trials
Acute Leukemia2 trials
Malignancies2 trials
Peritoneal Cancer2 trials
Advanced Malignancies2 trials
Refractory2 trials
Platinum-resistant Ovarian Cancer2 trials
Glioblastoma Multiforme1 trial
Safety and Efficacy1 trial
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Recruiting·—·Phase 1·NCT05101551·34 enrolled
Induction Chemotherapy1 trial
Malignant Brain Tumors1 trial
Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors
Terminated·NNicklaus Children's Hospital f/k/a Miami Children's Hospital·Phase 2·NCT02684071·3 enrolled
Ovarian Carcinoma1 trial
Metastasis1 trial
Relapsed or Refractory1 trial
Liposomal Doxorubicin1 trial
Soft Tissue Sarcoma1 trial
Rhabdomyosarcoma1 trial
Refractory or Recurrent Solid Tumor1 trial
Patients With Solid Tumors1 trial
Small Cell Cancer1 trial
Advanced Solid Malignancies1 trial
Impaired Renal Function1 trial
Papilloma1 trial
Glioblastoma1 trial
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
Completed·—·Phase 2·NCT01004874·80 enrolled
SCLC1 trial
Study in Patients With SCLC of Veliparib in Combination With Topotecan
Unknown status·CCentral European Society for Anticancer Drug Research·Phase 1·NCT03227016·30 enrolled
PARP Inhibitor1 trial
Malignant Glioma1 trial
Chronic CED of TPT for Recurrent Malignant Glioma
Recruiting·—·Phase 1·NCT06666712·6 enrolled
Relapse1 trial
Metastatic Colorectal Cancer1 trial
Meningitis1 trial
Phase 1 Intrathecal Topotecan for Neoplastic Meningitis
Completed·—·Phase 1·NCT00674674·22 enrolled
Celecoxib1 trial
Bevacizumab1 trial
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Completed·—·Phase 2·NCT00343044·40 enrolled
COVID-191 trial
Solid Neoplasms1 trial
Clinical Trial1 trial
Clear Cell Carcinoma1 trial
Chronic1 trial
Chronic Convection Enhanced Delivery of Topotecan
Completed·—·Phase 1·NCT03154996·5 enrolled
Recurrent1 trial
Progressive Multifocal Leukoencephalopathy1 trial
Rectal Carcinoma1 trial
Metastatic Ewing Sarcoma1 trial
Ganglioneuroblastoma, Nodular1 trial
Small Cell Lung Carcinoma (SCLC)1 trial
Ovarian Neoplasms1 trial
Small Cell Lung Carcinoma1 trial
Malignant Rhabdoid Tumor1 trial
Recurrent or Metastatic Cervical Cancer1 trial
Unspecified4 trials
Cabozantinib With Topotecan-Cyclophosphamide
Completed·—·Phase 1·NCT04661852·12 enrolled
Regulatory
FDA Approval Timeline[5]
May 28, 1996
HYCAMTIN
NDA NDA020671
Oct 11, 2007
HYCAMTIN
NDA NDA020981
Feb 2, 2011
TOPOTECAN HYDROCHLORIDE
NDA NDA200582
Feb 25, 2011
TOPOTECAN
NDA NDA200199
Dec 20, 2012
TOPOTECAN HYDROCHLORIDE
NDA NDA022453
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Hycamtin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Topotecan. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]